A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Inclusion Criteria:

   - Has prior history of varicella, antibodies to VZV (documented prior to receipt of
   blood products), or residence in a country with endemic VZV infection for ≥30 years or
   if participant is <30 years old, attended primary or secondary school in a country
   with endemic VZV infection.

   - Scheduled to undergo an autologous hematopoietic cell transplant within 60 days of
   enrollment

   - Is highly unlikely to conceive during the time period starting 2 weeks prior to
   enrollment through 6 months from last vaccination dose

   - Female participants of childbearing potential must have a negative serum or urine

pregnancy test.

Exclusion Criteria:

   - History of hypersensitivity reaction to any vaccine component

   - Prior history of herpes zoster within 1 year of enrollment

   - Prior receipt of any varicella or zoster vaccine

   - More than 2 relapses of the underlying cancer (participants with Hodgkin's lymphoma
   may have had more than 2 relapses)

   - Expectation of tandem transplant procedure

   - Is expected to receive >6 months (>180 days) of prophylactic antiviral therapy
   post-HCT.

   - Is pregnant or breastfeeding or expecting to conceive within the period of 2 weeks
   prior to enrollment through 6 months from last vaccination dose.

   - Has received a live virus vaccine or is scheduled to receive a live virus vaccine in
   the period from 4 weeks prior to Dose 1 through 28 days Postdose 4.

   - Has received an inactivated vaccine or is scheduled to receive an inactivated vaccine
   in the period between 7 days prior to and 28 days following Doses 1 through 4.